US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

周一，H.C. Wainwright调整了对Alector Inc. (NASDAQ:ALEC)股票的展望，将目标价从之前的35.00美元大幅下调至7.00美元，但仍维持买入评级。这一决定是在Alector宣布其针对阿尔茨海默病患者的TREM2抗体AL002的Phase 2 INVOKE-2试验未能达到主要终点后作出的。

Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of ...

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...